Alkermes Announces Results from Phase 2 Study of ALKS 33 for Treatment of Binge Eating Disorder
WALTHAM, Mass., Jul 07, 2011 (BUSINESS WIRE) -- Alkermes, Inc. (NASDAQ:ALKS) today announced topline results from a phase 2 clinical study of ALKS 33 in the treatment of binge eating disorder. This randomized, double-blind, placebo-controlled, 12-week study was designed to assess the safety and ...
No comments:
Post a Comment